Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNMT1 | P26358 | 6/20 | 0.65 |
| ▸ | DNMT3L | Q9UJW3 | 5/20 | 0.65 |
| ▸ | DNMT3A | Q9Y6K1 | 5/20 | 0.65 |
| ▸ | EHMT1 | Q9H9B1 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 5/20 | 0.52 |
| ▸ | MEN1 | O00255 | 5/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | MYC | P01106 | 1/20 | 0.52 |
| ▸ | MAP2K3 | P46734 | 1/20 | 0.52 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.52 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.52 |
| ▸ | ABCC1 | P33527 | 2/20 | 0.51 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12672276 | 0.91 | DNMT1 (0.64) | DNMT1DNMT3LDNMT3AEHMT1MAPT | |
| SCHEMBL1886837 | 0.90 | DNMT1 (0.80) | DNMT1DNMT3LDNMT3AEHMT1MAPT | |
| SCHEMBL1887399 | 0.90 | DNMT1 (0.80) | DNMT1DNMT3LDNMT3AEHMT1MAPT | |
| Hydrochloric Acid SCHEMBL1886545 | 0.90 | DNMT1 (0.62) | DNMT1DNMT3LDNMT3AEHMT1MAPT | |
| SCHEMBL1890995 | 0.87 | DNMT1 (0.73) | DNMT1DNMT3LDNMT3AEHMT1MAPT | |
| SCHEMBL1888633 | 0.84 | DNMT1 (0.62) | DNMT1DNMT3LDNMT3AEHMT1MAPT | |
| SCHEMBL1886243 | 0.84 | DNMT1 (0.62) | DNMT1DNMT3LDNMT3AEHMT1MAPT | |
| SCHEMBL3068523 | 0.82 | ABCC1 (0.68) | DNMT1DNMT3LDNMT3AMAPTKMT2A | |
| SCHEMBL3061369 | 0.81 | ABCC1 (0.64) | DNMT1DNMT3LDNMT3AMAPTMEN1 | |
| SCHEMBL3709576 | 0.80 | KMT2A (0.54) | DNMT1DNMT3LDNMT3AEHMT1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110256092-A1 | QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION | SUPERGEN, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-7939546-B2 | Quinoline derivatives for modulating DNA methylation | SUPERGEN, INC. (US) | 2011-05-10 | — | — | US | disclosed |
| US-7790746-B2 | Quinoline derivatives for modulating DNA methylation | SUPERGEN, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| EP-2205586-A1 | QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION | SuperGen, Inc. (US) | 2010-07-14 | — | — | EP | disclosed |
| US-20100129320-A1 | QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION | SUPERGEN, INC. (US) | 2010-05-27 | — | — | US | disclosed |
| EP-2174938-A1 | Quinoline derivatives for modulating DNA methylation | SuperGen, Inc. (US) | 2010-04-14 | — | — | EP | disclosed |
| US-20090285772-A1 | QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION | SUPERGEN, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| US-20090099106-A1 | QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION | SUPERGEN, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| WO-2009049132-A1 | QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION | SUPERGEN, INC. (US) | 2009-04-16 | — | — | WO | disclosed |
| US-20080175814-A1 | QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION | SUPERGEN, INC. (US) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080175814-A1 | QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION | DNMT1, DNMT3A, DNMT3L | DNMT1 1/4885DNMT3L 3/4885DNMT3A 2/4885 |
| US-20110256092-A1 | QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION | DNMT1, DNMT3A, DNMT3L | DNMT1 1/4885DNMT3L 3/4885DNMT3A 2/4885 |
| US-20090285772-A1 | QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION | DNMT1, DNMT3A, DNMT3L | DNMT1 1/4885DNMT3L 3/4885DNMT3A 2/4885 |
| US-20090099106-A1 | QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION | DNMT1, DNMT3A, DNMT3L | DNMT1 1/4885DNMT3L 3/4885DNMT3A 2/4885 |
| US-20100129320-A1 | QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION | DNMT1, DNMT3A, DNMT3L | DNMT1 1/4885DNMT3L 3/4885DNMT3A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.